Mucormycosis
Conditions
Keywords
Mucormycosis, Intensive Care Medicine
Brief summary
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.
Detailed description
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU). ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to : * their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression * the characteristics of the fungal infection * the treatment strategy * the severity of the initial illness, evaluated by severity scores Twenty-one French ICU are currently including more than 45 patients.
Interventions
None listed
Sponsors
University Hospital, Grenoble
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* confirmed or suspected mucormycosis, based on international definition from EORTC/MSG * patient hospitalized in intensive care unit during the 2008-2016 period * Zygomycosis identification in at least 2 solids organs or identification in hemoculture
Exclusion criteria
* Age under 18 years old * Patient under the law
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality at Day 28 | up to 28 days | Mortality at Day 28 after ICU admission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality during the ICU stage | up to 28 days | Mortality status (alive or dead) at the end of the ICU stage |
| Length stay in ICU | up to 28 days | number of days in intensive care Unit |
| Mortality at Day 90 | up to 90 days | Mortality at Day 90 after ICU admission |
| Mortality during the hospitalization | up to 90 days | Mortality status (alive or dead) at the end of the hospitalization |
| Prognostic criteria | up to 28 days | Prognostic factors of mortality in intensive care units |
| Length stay of hospitalization | up to 90 days | number of days in hospital |
Countries
France
Outcome results
None listed